Fully synthetic carbohydrate-based vaccines in biochemically relapsed prostate cancer: clinical trial results with alpha-N-acetylgalactosamine-O-serine/threonine conjugate vaccine. - Wikidata - awgldk - TriplyDB

Fully synthetic carbohydrate-based vaccines in biochemically relapsed prostate cancer: clinical trial results with alpha-N-acetylgalactosamine-O-serine/threonine conjugate vaccine.

Fully synthetic carbohydrate-based vaccines in biochemically relapsed prostate cancer: clinical trial results with alpha-N-acetylgalactosamine-O-serine/threonine conjugate vaccine.

http://www.wikidata.org/entity/Q44674111

about

Deciphering Structural Elements of Mucin Glycoprotein Recognition Immunotherapy in metastatic prostate cancer Deletion of atbf1/zfhx3 in mouse prostate causes neoplastic lesions, likely by attenuation of membrane and secretory proteins and multiple signaling pathways.Resolving conflicting data on expression of the Tn antigen and implications for clinical trials with cancer vaccines Increasing the antigenicity of synthetic tumor-associated carbohydrate antigens by targeting Toll-like receptors Robust immune responses elicited by a fully synthetic three-component vaccine.Antibody recognition of fluorinated MUC1 glycopeptide antigens.Cancer vaccines and carbohydrate epitopes.A novel cancer immunotherapy based on the combination of a synthetic carbohydrate-pulsed dendritic cell vaccine and glycoengineered cancer cells.Targeting novel antigens for prostate cancer treatment: focus on prostate-specific membrane antigen.Recent Development in Carbohydrate Based Anti-cancer Vaccines.Tobacco mosaic virus as a new carrier for tumor associated carbohydrate antigens.Carbohydrate vaccines as immunotherapy for cancer.Evaluation of human antibody responses to keyhole limpet hemocyanin on a carbohydrate microarray.Synthetic carbohydrate-based antitumor vaccines: challenges and opportunities.Effects of hapten density on the induced antibody repertoire Carbohydrate-based experimental therapeutics for cancer, HIV/AIDS and other diseases Scalable synthesis of Fmoc-protected GalNAc-threonine amino acid and T(N) antigen via nickel catalysis.Chemical glycosylation in the synthesis of glycoconjugate antitumour vaccines.Natural and synthetic saponin adjuvant QS-21 for vaccines against cancer.Aberrant O-glycosylation and anti-glycan antibodies in an autoimmune disease IgA nephropathy and breast adenocarcinoma.Tribulations or triumphs in prostate cancer immunotherapy: on the road to victory?A vision for vaccines built from fully synthetic tumor-associated antigens: from the laboratory to the clinic Microarrays with varying carbohydrate density reveal distinct subpopulations of serum antibodies.Postoperative change of anti-Thomsen-Friedenreich and Tn IgG level: the follow-up study of gastrointestinal cancer patients A newly generated functional antibody identifies Tn antigen as a novel determinant in the cancer cell-lymphatic endothelium interaction A new model for the presentation of tumor-associated antigens and the quest for an anticancer vaccine: a solution to the synthesis challenge via ring-closing metathesis.Combining synthetic carbohydrate vaccines with cancer cell glycoengineering for effective cancer immunotherapy.Carbohydrate vaccines: developing sweet solutions to sticky situations?Immunotherapy for cancer: synthetic carbohydrate-based vaccines.Phase I clinical trial of an adenovirus/prostate-specific antigen vaccine for prostate cancer: safety and immunologic results.Recent development in carbohydrate-based cancer vaccines.Prospects for total synthesis: a vision for a totally synthetic vaccine targeting epithelial tumors.Tumor-associated glycans and their role in gynecological cancers: accelerating translational research by novel high-throughput approaches.Synthetic carbohydrate-based anticancer vaccines: the Memorial Sloan-Kettering experience.Carbohydrate-based vaccines: challenges and opportunities.The Tn antigen-structural simplicity and biological complexity.Toward automated oligosaccharide synthesis.Prostate cancer vaccines: moving therapeutic vaccination forward in the post-Provenge era.Prostate cancer vaccines in clinical trials.

P2860

Q27678183-A3886C1A-5D04-4B21-85B5-4C1CA77C2BDB Q28072081-DAC07909-0D71-4D79-8458-80EEA609C647 Q30410016-6CFAC198-F45B-4917-B708-2403A06C7BBD Q33431143-A4552F56-7728-42EB-B365-E7064D33E6E9 Q33591916-8809F10F-C144-408F-9C8A-D7444448E0F1 Q33721005-40AF0AA7-88C9-47A2-A981-6363789F5B05 Q34045866-947D3869-03D3-4153-A85F-D15B28B34493 Q35525289-74D3D5A7-C9A3-4D97-8129-E0E4E9B7D645 Q35741638-275AD323-C5BC-453E-8C66-FF9D564BE16A Q35758285-832BB44E-6F5E-47A4-B119-783297ECB35B Q35854131-F4CA135C-B085-41F4-9301-018B54F96548 Q36186712-25BB5A1C-F9F6-4E34-9A9E-49CF4C7FAD7F Q36201691-FB0C07FB-76CC-4370-8CC5-11FA8F47B1AA Q36278684-8905959C-A84E-477E-BBC1-903BF9360D32 Q36284550-8FCDA3FA-25A3-487D-A4C4-9039E1B973E4 Q36292042-0A52B931-44F9-4FAF-A95A-6BD2714A434B Q36515536-672CB897-DB5D-475D-ADF5-FE1F604D05AC Q36576120-CFEDB340-55E9-4172-8897-086F155421C9 Q36802325-05EFF2D8-5FBD-4E82-A6E2-E2D84E4B7D2A Q36856279-C1E4E3DA-A4B8-4400-86FD-9DC5D62CE31A Q37100578-B53C6B38-E10C-4007-8AA8-F5C43743BE77 Q37118960-9F510084-2651-4E77-B560-9DC94ED7CEE3 Q37303845-3B70C98E-15AD-4276-952D-AA946AB26E56 Q37315367-7869E9FD-2E70-4A92-97B9-EAE93F30473B Q37316672-AC54DB4C-CC3A-4C09-9E3A-E8ACB05002F5 Q37328722-96E5DC38-3038-4161-B17C-E6614D53F796 Q37380026-CA9304C6-F6AC-4561-8B62-5ECF72A7B60E Q37418500-2383861F-8637-4B19-A0DE-C997146CB0E9 Q37426039-60DB6085-0F29-4EF6-9035-F519E1432984 Q37453814-935A5313-2DBC-496E-B030-C1627A41247A Q37455348-3BA5DC84-DA9F-46E3-9EE0-4CC28C8EDB4E Q37455940-30F39272-CF2C-4048-90B9-63EBE7A3C0E0 Q37484024-CEE1D377-EFF7-4C8C-B3E2-A502365FA9F9 Q37512647-6C4C445D-5767-4094-9D01-723A7EE649AC Q37608314-B2CCBDFC-65A8-4BBD-83FC-6E44BB2D72A5 Q37810597-2366824B-86B7-4BAC-B77B-3E1FA79558BC Q37831859-44C9D5B6-6662-47F8-89F0-11A928B8071B Q37962848-EF5B5BBE-F558-4FB4-AF69-32E21881FA71 Q37989571-7B35B881-6722-4859-982D-F7ED14D1E395 Q38036690-9EF9C049-DBDD-4204-854D-DD20BC3C3F17

P2860

Fully synthetic carbohydrate-based vaccines in biochemically relapsed prostate cancer: clinical trial results with alpha-N-acetylgalactosamine-O-serine/threonine conjugate vaccine.

http://www.wikidata.org/entity/Q44674111

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年学术文章

@wuu

2003年学术文章

@zh-cn

2003年学术文章

@zh-hans

2003年学术文章

@zh-my

2003年学术文章

@zh-sg

2003年學術文章

@yue

2003年學術文章

@zh

2003年學術文章

@zh-hant

name

Fully synthetic carbohydrate-b ...... e/threonine conjugate vaccine.

@en

Fully synthetic carbohydrate-b ...... e/threonine conjugate vaccine.

@nl

type

label

Fully synthetic carbohydrate-b ...... e/threonine conjugate vaccine.

@en

Fully synthetic carbohydrate-b ...... e/threonine conjugate vaccine.

@nl

prefLabel

Fully synthetic carbohydrate-b ...... e/threonine conjugate vaccine.

@en

Fully synthetic carbohydrate-b ...... e/threonine conjugate vaccine.

@nl

P1433

Q44674111-F14749A0-76F6-45E3-B84E-170D2483B180

P1476

Q44674111-596DB0FF-1EB6-4648-9EF8-823AC32BE5B0

P2093

Q44674111-0FA2BAC8-0BF5-4A41-A7EF-BF7DC9B3BAD9

Q44674111-56E0B6B6-8168-40D2-8BD2-B7D54FBCFFEE

Q44674111-64A4B0ED-3B7E-41AA-9109-38221691FCED

Q44674111-7541389D-9B5A-4415-8167-0E700B3C43D9

Q44674111-8025FFEB-DDB4-48CD-8EC4-1EC0C3DC4A04

Q44674111-88DD80BA-1907-4BE3-9D3F-3818D9475B78

Q44674111-97DB02BA-A6BE-4E96-A3F8-73AB5E0F21C5

Q44674111-9EF03CF4-A3D6-4C6F-BA34-B5308D448DA5

Q44674111-A5A06118-071E-4ECE-8269-6A8FD8EBD6B7

Q44674111-D7BBD829-C27D-4659-A29F-BF0544CEBC7B

P304

Q44674111-D408D74B-6007-4E16-8131-C0C1E3DBD30A

P31

Q44674111-6E0AE2E5-5C78-44DE-A958-5244C8744E68

P356

Q44674111-227C519C-F18C-496F-A59E-F4424DFAA11B

P407

Q44674111-89EFCAA3-7128-4D4E-8915-8E1CC6D7A62F

P433

Q44674111-9970DB34-8013-4D31-B83C-A29644FBA8A7

P478

Q44674111-C09E856E-7E0E-46A7-B681-73187C0FD694

P577

Q44674111-98ABEC07-EA42-4DBD-9AE8-28F7617D9131

P698

Q44674111-79F81C17-0AF1-400A-BD69-A3BD428E0BE2

P356

JCO.2003.04.112

P1433

Journal of Clinical Oncology

P1476

Fully synthetic carbohydrate-b ...... e/threonine conjugate vaccine.

@en

P2093

Cristina Musselli

http://www.w3.org/2001/XMLSchema#string

Dalibor Sames

http://www.w3.org/2001/XMLSchema#string

David Verbel

http://www.w3.org/2001/XMLSchema#string

Govindaswami Ragupathi

http://www.w3.org/2001/XMLSchema#string

Howard I Scher

http://www.w3.org/2001/XMLSchema#string

Jacob B Schwarz

http://www.w3.org/2001/XMLSchema#string

Krystyna Olkiewicz

http://www.w3.org/2001/XMLSchema#string

Philip O Livingston

http://www.w3.org/2001/XMLSchema#string

Samuel Danishefsky

http://www.w3.org/2001/XMLSchema#string

Scott D Kuduk

http://www.w3.org/2001/XMLSchema#string

P304

4292-4298

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2003.04.112

http://www.w3.org/2001/XMLSchema#string

P407

P433

23

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P577

2003-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

14645418

http://www.w3.org/2001/XMLSchema#string